title: Comparing cystatin C changes as a measure of renal function before and after radiotherapy in patients with stomach cancer.
abstract: The objective of this study was to determine and compare cystatin C changes before and after radiotherapy in patients with stomach cancer who were candidate for radiotherapy. This study was conducted as a prospective cohort one. Eighteen patients with definite diagnosis of stomach cancer under treatment by radiotherapy who presented to Radiotherapy-Oncology Center of Imam Hossein Hospital, Tehran-Iran, and the treatment in all cases was simultaneous chemoradiation with Xeloda were included. In all patients before radiotherapy and after radiotherapy serum creatinine (Cr) and cystatin C were measured simultaneously. Mean cystatin level before treatment (1.2 ± 0.4) was significantly lower than that of post-treatment (1.6 ± 0.36), (P=0.001). Serum Cr level before treatment was 1.15 ± 0.33 and after radiotherapy was 1.08 ± 0.24 and did not show significant difference. Glomerular filtration rate (GFR) of the patients before radiotherapy was -46.8 ± 21.0 and after radiotherapy was 43.8 ± 15.8 that did not have significant difference (P=0.146) and also blood urea nitrogen (BUN) before radiotherapy was 20.72 ± 3.7 and 20 ± 6.38 after radiotherapy that did not have significant difference (P=0.6). Comparison of the cystatin C difference with total radiation dose of the kidneys that are put in three dose groups in radiotherapy field had association that in dose of less that 18 gray (Gy) the cystatin C change showed significant and positive association (P=0.027; r=0.52) and about 18-24 Gy the cystatin C difference showed significant and negative association (P=0.023, r=-0.53). It seems that for evaluating the renal function, serum cystatin C measurement is preferable than serum Cr. level.
authors.affiliation: Department of Radiotherapy-Oncology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
authors.forename: Hooshang Amir
authors.initials: HA
authors.lastname: Rasouli
authors.forename: Maryam Mirzaie
authors.initials: MM
authors.lastname: Moghadam
authors.forename: Morteza
authors.initials: M
authors.lastname: Tabatabaiefar
authors.forename: Farnaz
authors.initials: F
authors.lastname: Taslimi
authors.forename: Khosro Mojir
authors.initials: KM
authors.lastname: Sheybani
authors.forename: Asadollah
authors.initials: A
authors.lastname: Alidoosti
authors.forename: Ahmad
authors.initials: A
authors.lastname: Ameri
authors.forename: Pedram
authors.initials: P
authors.lastname: Fadavi
authors.forename: Shahrzad
authors.initials: S
authors.lastname: Aref
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001806:Blood Urea Nitrogen; D000069287:Capecitabine; D059248:Chemoradiotherapy / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D055316:Cystatin C / Q000097:blood*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005919:Glomerular Filtration Rate; D006801:Humans; D007492:Iran; D007668:Kidney / Q000378:metabolism* / Q000503:physiopathology; D007674:Kidney Diseases / Q000097:blood / Q000175:diagnosis* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011829:Radiation Dosage; D011832:Radiation Injuries / Q000097:blood / Q000175:diagnosis* / Q000209:etiology / Q000503:physiopathology; D013274:Stomach Neoplasms / Q000097:blood / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D015415:Biomarkers; C525030:CST3 protein, human; D055316:Cystatin C; D003841:Deoxycytidine; D000069287:Capecitabine; D003404:Creatinine; D005472:Fluorouracil